Results 121 to 130 of about 662,207 (147)

SGLT2 inhibitor dapagliflozin treats heart failure with preserved ejection fraction via the SIRT1/PGC-1α pathway. [PDF]

Acta Biochim Biophys Sin (Shanghai)
Zhang S, Cui Y, Chen J, Zhou S, Zhang Y, Li K, Hou Y.   +6 more
europepmc   +1 more source

Disentangling Uric Acid and Renal Pathways in SGLT2 Inhibitor Effects After Acute Myocardial Infarction: A Retrospective Mediation Analysis. [PDF]

Biomedicines
Suciu IM, Muntean C, Gaiță L, Mateoc-Sîrb T, Vlad DC, Timar B, Gaiță D.   +6 more
europepmc   +1 more source

The SGLT2 inhibitor dapagliflozin alleviates ventricular remodeling and apoptosis after myocardial infarction by inhibiting the TGF-β1 and MAPK pathways. [PDF]

J Cardiothorac Surg
Zhu Z, Zhang Y, Fang Z, Li X, Ma C, Liu Q, Zhang Q, Zhu W, Su H, Xu X.   +9 more
europepmc   +1 more source

Lower Risk of Incident Dementia with SGLT2 Inhibitor Versus DPP-4 Inhibitor Initiation in Patients with Type 2 Diabetes and Prior Traumatic Brain Injury: A Retrospective Cohort Study. [PDF]

Drug Des Devel Ther
Hung KC, Weng HL, Chen IW.
europepmc   +1 more source

sncRNA levels predict SNORD105B is a novel biomarker of chronic kidney disease risk and SGLT2 inhibitor response in type 2 diabetes. [PDF]

Mol Ther Nucleic Acids
de Klerk JA, Slieker RC, Beulens JWJ, Peerlings JHD, Mei H, Elders PJM, van Zonneveld AJ, van Raalte DH, Bijkerk R, 't Hart LM.   +9 more
europepmc   +1 more source

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.

JAMA Netw Open
Chung MC, Yu TM, Wu LY, Wu MJ, Shieh JJ, Chung CJ.   +5 more
europepmc   +1 more source

SGLT2 inhibitor role in cardio-metabolic-renal diseases: a narrative review of recent evidence and their pharmacological, clinical and economic implications. [PDF]

Drugs Context
Manunta M, Bruno GM, Ferrantelli A, Ramirez RF, Nardi F.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials

Clinical Cardiology, 2021
Samuel Dagogo-Jack, Nikolaus Marx, Richard E. Pratley   +2 more
exaly